Amicus Therapeutics, Inc. (FOLD)

Market Cap	3.10B
Revenue (ttm)	329.23M
Net Income (ttm)	-236.57M
Shares Out	282.72M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,025,482
Open	11.22
Previous Close	11.23
Day's Range	10.85 - 11.29
52-Week Range	5.91 - 13.84
Beta	0.82
Analysts	Buy
Price Target	16.04 (+46.48%)
Earnings Date	May 8, 2023

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 31, 2007
• Employees: 496
• Stock Exchange: NASDAQ
• Ticker Symbol: FOLD

Financial Performance

In 2022, FOLD's revenue was $329.23 million, an increase of 7.76% compared to the previous year's $305.51 million. Losses were -$236.57 million, -5.55% less than in 2021.

Analyst Forecast

According to 19 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is $16.04, which is an increase of 46.48% from the latest price.

Price Target

$16.04

(46.48% upside)

Analyst Consensus: Buy